Use of abatacept in rheumatoid arthritis Recommendations based on current evidence

被引：19

作者：

von Kempis, Johannes ^{[1
]}

Dudler, Jean ^{[2
]}

Hasler, Paul ^{[3
]}

Kyburz, Diego ^{[4
,5
]}

Tyndall, Alan ^{[6
]}

Zufferey, Pascal ^{[7
]}

Villiger, Peter M. ^{[8
]}

机构：

[1] Kantonsspital, Dept Med, Div Rheumatol & Rehabil, CH-9007 St Gallen, Switzerland

[2] HFR Hop Cantonal Fribourg, Dept Rheumatol Phys Med & Rehabil, Fribourg, Switzerland

[3] Kantonsspital Aarau, Dept Rheumatol, Aarau, Switzerland

[4] Univ Zurich Hosp, Dept Rheumatol, Zurich, Switzerland

[5] Univ Zurich Hosp, Inst Phys Therapy, Zurich, Switzerland

[6] Univ Basel Hosp, Dept Rheumatol, Basel, Switzerland

[7] Univ Hosp Lausanne CHUV, Dept Rheumatol, Lausanne, Switzerland

[8] Univ Hosp Bern, Dept Rheumatol Clin Immunol & Allergol, Bern, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2012年 / 142卷

关键词：

abatacept; rheumatoid arthritis; recommendations; use; therapy; MODE;

D O I：

10.4414/smw.2012.13581

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naive RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.

引用

页数：7

共 27 条

[1] Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study [J].

Buch, M. H. ;

Boyle, D. L. ;

Rosengren, S. ;

Saleem, B. ;

Reece, R. J. ;

Rhodes, L. A. ;

Radjenovic, A. ;

English, A. ;

Tang, H. ;

Vratsanos, G. ;

O'Connor, P. ;

Firestein, G. S. ;

Emery, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (07) :1220-1227

[2]

Choy EH, 2009, CLIN EXP RHEUMATOL, V27, P510

[3]

DOUGADOS M, 2009, ANN RHEUM DIS, V68, P573

[4] Biologics in rheumatoid arthritis (RA) - recommendations for Swiss practice [J].

Dudler, Jean ;

Moeller, Burkhard ;

Michel, Beat A. ;

Villiger, Peter M. .

SWISS MEDICAL WEEKLY, 2011, 141

[5]

Durez P, 2010, EULAR ANN C JUN 16 1

[6]

Genant HK, 2009, EULAR ANN C JUN 10 1

[7] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [J].

Genovese, MC ;

Becker, J ;

Schiff, M ;

Luggen, M ;

Sherrer, Y ;

Kremer, J ;

Birbara, C ;

Box, J ;

Natarajan, K ;

Nuamah, I ;

Li, T ;

Aranda, R ;

Hagerty, DT ;

Dougados, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1114-1123

[8]

Hochberg MH, 2010, ACR ARHP ANN SCI M N

[9]

Janeway CA., 2005, IMMUNOBIOLOGY, V6, P319

[10]

Keystone E, 2010, ARTHRITIS RHEUMATI S, V62, pS470

← 1 2 3 →